Changes in Hong Kong stocks | Yinnuo Pharmaceutical-B (02591) rose more than 5% to officially enter Hang Seng Composite Index next Monday, claiming that it is within the scope of Hong Kong Stock Connect

Zhitongcaijing · 1d ago

The Zhitong Finance App learned that Yinnuo Pharmaceutical-B (02591) has increased by more than 5%, and the stock price is currently in the current three-day period. As of press release, it rose 5.03% to HK$43.42, with a turnover of HK$7.6433 million.

According to the news, the results of the Hang Seng Index series quarterly review were announced earlier. Among them, Yinnuo Pharmaceuticals was included as a constituent stock of the Hang Seng Composite Index, and the changes will take effect on December 8, 2025. According to CICC's forecast, Yinnuo Pharmaceuticals and the like are covered by the Hong Kong Stock Connect. According to public information, Yinnuo Pharmaceutical is a biomedical company focusing on metabolic diseases. Currently, it has a number of innovative drug research and development pipelines for indications such as diabetes, obesity, and non-alcoholic steatohepatitis. All of them are independently developed, have global intellectual property rights, and cover global R&D and market layout.